## SD220811-022 page 1 of 1

## PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

## sample Haymaker - Pink Rozay

Sample ID SD220811-022 (50953)		Matrix Concentrate (Inhalable Cannabis Good)
Tested for Latro inc		
Sampled -	Received Aug 11, 2022	Reported Aug 12, 2022
Angluses executed CANX		

Laboratory note: The estimated concentration of the unknown peak in the sample is 3.64% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC, (+)d8-THC is a different compound from the main (-)d8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be 44.76%.

## CANX - Cannabinoids Analysis

Analyzed Aug 12, 2022 | Instrument HLPC Measurement Uncertainty at 95% confidence7.806%

Inalyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	
1-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	NT	NT	
Cannabidiorcin (CBDO)	0.002	0.007	NT	NT	
bnormal Cannabidiorcin (a-CBDO)	0.01	0.031	NT	NT	
+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC)	0.012	0.036	NT	NT	
1-Hydroxy-∆8-Tetrahydrocannabinol (11-Hyd-∆8-THC)	0.007	0.021	NT	NT	
Cannabidiolic Acid (CBDA)	0.001	0.16	ND	ND	
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND	
Cannabigerol (CBG)	0.001	0.16	ND	ND	
Cannabidiol (CBD)	0.001	0.16	ND	ND	100
(S)-THD (s-THD)	0.013	0.041	NT	NT	
(R)-THD (r-THD)	0.025	0.075	NT	NT	
etrahydrocannabivarin (THCV)	0.001	0.16	ND	ND	
\8-tetrahydrocannabivarin (Δ8-THCV)	0.021	0.064	NT	NT	
etrahydrocannabutol (Δ9-THCB)	0.013	0.038	NT	NT	
Cannabinol (CBN)	0.001	0.16	ND	ND	
Cannabidiphorol (CBDP)	0.015	0.047	NT	NT	
xo-THC (exo-THC)	0.016	0.8	ND	ND	
etrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI	
8-tetrahydrocannabinol (∆8-THC)	0.004	0.16	61.12	611.21	
6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.16	ND	ND	
lexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.16	ND	ND	
6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.16	ND	ND	
lexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	ND	ND	
etrahydrocannabinolic Acid (THCA)	0.001	0.16	ND	ND	
l9-Tetrahydrocannabihexol (Δ9-THCH)	0.024	0.071	ND	ND	
Cannabinol Acetate (CBNO)	0.014	0.043	NT	NT	
l9-Tetrahydrocannabiphorol (Δ9-THCP)	0.017	0.16	6.15	61.51	
\8-Tetrahydrocannabiphorol (Δ8-THCP)	0.041	0.16	ND	ND	
\8-THC-O-acetate (Δ8-THCO)	0.076	0.16	24.47	244.75	
(S)-HHCP (s-HHCP)	0.031	0.094	NT	NT	
9-THC-O-acetate (Δ9-THCO)	0.066	0.16	1.78	17.84	
(R)-HHCP (r-HHCP)	0.026	0.079	NT	NT	
-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	NT	NT	
Cannabichromene (CBC)	0.002	0.16	ND	ND	
Cannabidivarin (CBDV)	0.039	0.16	ND	ND	
otal THC ( THCa * 0.877 + Δ9THC )			ND	ND	
otal THC + Δ8THC + Δ10THC ( THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC )			61.12	611.21	
otal CBD ( CBDa * 0.877 + CBD )			ND	ND	
otal CBG ( CBGa * 0.877 + CBG )			ND	ND	
otal HHC ( 9r-HHC + 9s-HHC )			ND	ND	



tography

UI Not Identified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Otenctification <LOQ Detected >ULQL Above upper limit of linearity >ULQL Above upper limit of linearity CFU/Q colong Forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Fri, 12 Aug 2022 08:20:47 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 "This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fall status is reported, that status is intended to be in accordance with federal, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fall evolution unless explicition unless explicition, state or local lows and has been reported on the retrificate of analysis. Measurement of uncertainty is available unprequest.

**QA** Testing

